[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

August 2017 - April 2015

Decade

Year

Issue

June 2015, Vol 1, No. 3, Pages 263-394

Viewpoint

Addressing the Financial Burden of Cancer TreatmentFrom Copay to Can’t Pay

Abstract Full Text
free access
JAMA Oncol. 2015;1(3):273-274. doi:10.1001/jamaoncol.2015.0423

This Viewpoint presents 5 strategies to lessen the financial burden of cancer treatment.

Using Somatic Mutations to Guide Treatment DecisionsContext Matters

Abstract Full Text
free access
JAMA Oncol. 2015;1(3):275-276. doi:10.1001/jamaoncol.2015.35

This Viewpoint describes how consideration of the cellular and genomic context in which somatic mutations occur will be required for the optimal targeting of cancer treatments.

Multigene Panel Testing in Oncology PracticeHow Should We Respond?

Abstract Full Text
free access
JAMA Oncol. 2015;1(3):277-278. doi:10.1001/jamaoncol.2015.28

Concerns have arisen that technical advances in genomics have outpaced our ability to provide safe, ethical care. When guided by appropriate expertise and in conjunction with clinical research, however, multigene panels offer substantial opportunities to improve cancer risk assessment, early detection, and prevention.

Cancer Care Chronicles

Patient Trust—Keeping It in the Family

Abstract Full Text
free access
JAMA Oncol. 2015;1(3):279-280. doi:10.1001/jamaoncol.2015.0370

A family experience with cancer brings the author to a deeper understanding of the importance of trust in the physician-patient relationship.

The author illustrates through personal narrative how patient trust is necessary for successful patient-physician discussions of treatment options in cases of serious illness.

Editorial

Thiopurines for the Treatment of Acute Lymphoblastic Leukemia in ChildrenWhat’s Old Is New

Abstract Full Text
free access
JAMA Oncol. 2015;1(3):281-282. doi:10.1001/jamaoncol.2015.0435

Progesterone Exposure and Breast Cancer RiskUnderstanding the Biological Roots

Abstract Full Text
free access
JAMA Oncol. 2015;1(3):283-285. doi:10.1001/jamaoncol.2015.0512
Original Investigation

Systemic Exposure to Thiopurines and Risk of Relapse in Children With Acute Lymphoblastic LeukemiaA Children’s Oncology Group Study

Abstract Full Text
free access
JAMA Oncol. 2015;1(3):287-295. doi:10.1001/jamaoncol.2015.0245

Children in remission from acute lymphoblastic leukemia and undergoing maintenance therapy with 6-mercaptopurine are at greater risk of relapse if their drug intake is not regularized and closely monitored.

Breast Cancer After Use of Estrogen Plus Progestin and Estrogen AloneAnalyses of Data From 2 Women’s Health Initiative Randomized Clinical Trials

Abstract Full Text
free access
JAMA Oncol. 2015;1(3):296-305. doi:10.1001/jamaoncol.2015.0494

This study examined the influences of hormone therapy on breast cancer incidence during early and late postintervention phases in the Women’s Health Initiative trials, finding greater adverse influence for estrogen + progestin use and somewhat greater benefit for use of estrogen alone.

Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers

Abstract Full Text
free access
JAMA Oncol. 2015;1(3):306-313. doi:10.1001/jamaoncol.2015.0658

This retrospective study found that oophorectomy is associated with a decrease in mortality in women with breast cancer and a BRCA1 mutation.

5α-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer

Abstract Full Text
free access
JAMA Oncol. 2015;1(3):314-320. doi:10.1001/jamaoncol.2015.0387

In a retrospective study to determine whether the use of 5α-reductase inhibitors before prostate cancer diagnosis is associated with an increased risk of cancer-specific and all-cause mortality, the authors found no association.

The Influence of Hospital and Surgeon Factors on the Prevalence of Axillary Lymph Node Evaluation in Ductal Carcinoma In Situ

Abstract Full Text
free access
JAMA Oncol. 2015;1(3):323-332. doi:10.1001/jamaoncol.2015.0389

This cross-sectional study finds that axillary evaluation is often conducted in women treated for ductal carcinoma in situ despite guidelines against its use with breast-conserving surgery and uncertainty of benefit with mastectomy.

Risk Group and Death From Prostate CancerImplications for Active Surveillance in Men With Favorable Intermediate-Risk Prostate Cancer

Abstract Full Text
free access
JAMA Oncol. 2015;1(3):334-340. doi:10.1001/jamaoncol.2014.284

Men with low-risk and favorable intermediate-risk prostate cancer have similarly low mortality during the first decade after standard brachytherapy, thus supporting initial management of active surveillance for both groups.

Difference in Association of Obesity With Prostate Cancer Risk Between US African American and Non-Hispanic White Men in the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

Abstract Full Text
free access
JAMA Oncol. 2015;1(3):342-349. doi:10.1001/jamaoncol.2015.0513

This prospective study found that obesity is more strongly associated with increased prostate cancer risk among African American than non-Hispanic white men and thus reducing obesity among African American men could reduce the racial disparity in cancer incidence.

Increased Plasma Levels of Chemoresistance-Inducing Fatty Acid 16:4(n-3) After Consumption of Fish and Fish Oil

Abstract Full Text
JAMA Oncol. 2015;1(3):350-358. doi:10.1001/jamaoncol.2015.0388

This explorative study finds that ingestion of fish oils and fishes containing relevant levels of 16:4(n-3) should be avoided on days surrounding chemotherapy to avoid potent chemotherapy-negating effects found in preclinical mouse models.

Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma

Abstract Full Text
free access
JAMA Oncol. 2015;1(3):359-368. doi:10.1001/jamaoncol.2015.0493

In this study of tumor characteristics and melanoma-specific survival, NRAS+ and BRAF+ melanomas were found to be associated with higher tumor stage at diagnosis, indicating that these melanomas are less likely than wildtype melanoma to be diagnosed when lower risk and surgically curable.

Brief Report

Effect of Unblinding on Participants' Perceptions of Risk and Confidence in a Large Double-Blind Clinical Trial of Chemotherapy for Breast Cancer

Abstract Full Text
free access
JAMA Oncol. 2015;1(3):369-374. doi:10.1001/jamaoncol.2015.0246

This survey study found that in a placebo-controlled, double-blind randomized clinical trial of breast cancer chemotherapy, unblinding to randomization allocation did not significantly affect most participants’ views except for chance of a serious problem from experimental treatment.

Invited Commentary

Effect of 5α-Reductase Inhibitor Use on Mortality From Prostate Cancer

Abstract Full Text
free access
JAMA Oncol. 2015;1(3):321-322. doi:10.1001/jamaoncol.2015.0408

Use of Axillary Staging in the Management of Ductal Carcinoma In Situ

Abstract Full Text
free access
JAMA Oncol. 2015;1(3):332-333. doi:10.1001/jamaoncol.2015.0390

Active Surveillance in Prostate CancerHow Far Should We Go?

Abstract Full Text
free access
JAMA Oncol. 2015;1(3):340-341. doi:10.1001/jamaoncol.2015.103
Special Communication

Patient-Reported Outcomes in Cancer Drug Development and US Regulatory ReviewPerspectives From Industry, the Food and Drug Administration, and the Patient

Abstract Full Text
free access
JAMA Oncol. 2015;1(3):375-379. doi:10.1001/jamaoncol.2015.0530

This Special Communication provides perspectives regarding the rationale, barriers, and strategies for integrating patient-reported outcome end points and guidance principles into cancer drug development and US labeling.

Review

Therapeutic Advances and Treatment Options in Metastatic Melanoma

Abstract Full Text
free access has active quiz
JAMA Oncol. 2015;1(3):380-386. doi:10.1001/jamaoncol.2015.0565

This review discusses the development of targeted and immune therapies for advanced melanoma, reviews current patient management, and highlights future directions.

From The JAMA Network

Combination Immunotherapy for Melanoma

Abstract Full Text
free access
JAMA Oncol. 2015;1(3):387-388. doi:10.1001/jamaoncol.2015.0479
Editor's Note

Adjuvant Oophorectomy in the Treatment of Early-Stage BRCA Mutation–Positive Breast Cancer

Abstract Full Text
free access
JAMA Oncol. 2015;1(3):313. doi:10.1001/jamaoncol.2015.0708

Targeted Reduction in Body Mass Index Is a Worthwhile Risk Reduction Strategy for Prostate Cancer

Abstract Full Text
free access
JAMA Oncol. 2015;1(3):349. doi:10.1001/jamaoncol.2015.0514
Correction

Error in Reference List

Abstract Full Text
free access
JAMA Oncol. 2015;1(3):280. doi:10.1001/jamaoncol.2015.0948

Error in Text

Abstract Full Text
free access
JAMA Oncol. 2015;1(3):285. doi:10.1001/jamaoncol.2015.1781

Incorrect Academic Degree

Abstract Full Text
free access
JAMA Oncol. 2015;1(3):322. doi:10.1001/jamaoncol.2015.1791
JAMA Oncology Patient Page

Circulating Tumor Cells

Abstract Full Text
free access
JAMA Oncol. 2015;1(3):394. doi:10.1001/jamaoncol.2015.0711
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2015;1(3):268. doi:10.1001/jamaoncol.2014.245
In This Issue of JAMA Oncology

Highlights

Abstract Full Text
free access
JAMA Oncol. 2015;1(3):263. doi:10.1001/jamaoncol.2015.0724
×